Logo image of VIR

VIR BIOTECHNOLOGY INC (VIR) Stock Fundamental Analysis

NASDAQ:VIR - Nasdaq - US92764N1028 - Common Stock - Currency: USD

9.57  -0.23 (-2.35%)

After market: 9.9599 +0.39 (+4.07%)

Fundamental Rating

4

VIR gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for VIR as it has an excellent financial health rating, but there are worries on the profitability. VIR is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year VIR has reported negative net income.
VIR had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: VIR reported negative net income in multiple years.
In the past 5 years VIR reported 4 times negative operating cash flow.
VIR Yearly Net Income VS EBIT VS OCF VS FCFVIR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 0 500M -500M 1B 1.5B

1.2 Ratios

Looking at the Return On Assets, with a value of -35.60%, VIR is in the better half of the industry, outperforming 61.63% of the companies in the same industry.
VIR has a better Return On Equity (-42.99%) than 70.16% of its industry peers.
Industry RankSector Rank
ROA -35.6%
ROE -42.99%
ROIC N/A
ROA(3y)4.47%
ROA(5y)-10.64%
ROE(3y)7.69%
ROE(5y)-11.96%
ROIC(3y)N/A
ROIC(5y)N/A
VIR Yearly ROA, ROE, ROICVIR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 20 -20 -40 -60 -80

1.3 Margins

VIR has a Gross Margin of 98.78%. This is amongst the best in the industry. VIR outperforms 98.22% of its industry peers.
The Profit Margin and Operating Margin are not available for VIR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 98.78%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VIR Yearly Profit, Operating, Gross MarginsVIR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K

More info and screens

7

2. Health

2.1 Basic Checks

VIR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VIR has more shares outstanding
Compared to 5 years ago, VIR has more shares outstanding
VIR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
VIR Yearly Shares OutstandingVIR Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
VIR Yearly Total Debt VS Total AssetsVIR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B 2B 2.5B

2.2 Solvency

An Altman-Z score of 2.07 indicates that VIR is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of VIR (2.07) is better than 71.05% of its industry peers.
VIR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.07
ROIC/WACCN/A
WACC9.44%
VIR Yearly LT Debt VS Equity VS FCFVIR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 500M -500M 1B 1.5B 2B

2.3 Liquidity

A Current Ratio of 8.94 indicates that VIR has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 8.94, VIR is in the better half of the industry, outperforming 76.02% of the companies in the same industry.
VIR has a Quick Ratio of 8.94. This indicates that VIR is financially healthy and has no problem in meeting its short term obligations.
VIR has a better Quick ratio (8.94) than 76.20% of its industry peers.
Industry RankSector Rank
Current Ratio 8.94
Quick Ratio 8.94
VIR Yearly Current Assets VS Current LiabilitesVIR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B 2B 2.5B

More info and screens

6

3. Growth

3.1 Past

VIR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.69%, which is quite good.
The Revenue for VIR has decreased by -33.82% in the past year. This is quite bad
VIR shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 51.78% yearly.
EPS 1Y (TTM)12.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.87%
Revenue 1Y (TTM)-33.82%
Revenue growth 3Y4.1%
Revenue growth 5Y51.78%
Sales Q2Q%-9.81%

3.2 Future

VIR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.45% yearly.
VIR is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 27.39% yearly.
EPS Next Y13.59%
EPS Next 2Y8.8%
EPS Next 3Y6.96%
EPS Next 5Y9.45%
Revenue Next Year-12.53%
Revenue Next 2Y-37.81%
Revenue Next 3Y-21.54%
Revenue Next 5Y27.39%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
VIR Yearly Revenue VS EstimatesVIR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B
VIR Yearly EPS VS EstimatesVIR Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VIR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VIR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VIR Price Earnings VS Forward Price EarningsVIR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VIR Per share dataVIR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.8%
EPS Next 3Y6.96%

More info and screens

0

5. Dividend

5.1 Amount

VIR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIR BIOTECHNOLOGY INC

NASDAQ:VIR (2/21/2025, 8:00:01 PM)

After market: 9.9599 +0.39 (+4.07%)

9.57

-0.23 (-2.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-31 2024-10-31/amc
Earnings (Next)02-26 2025-02-26/amc
Inst Owners61.8%
Inst Owner Change2.09%
Ins Owners2.58%
Ins Owner Change3.38%
Market Cap1.32B
Analysts78.46
Price Target21.59 (125.6%)
Short Float %7.61%
Short Ratio3.29
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-29.76%
Min EPS beat(2)-46.72%
Max EPS beat(2)-12.81%
EPS beat(4)2
Avg EPS beat(4)2.7%
Min EPS beat(4)-46.72%
Max EPS beat(4)54.8%
EPS beat(8)2
Avg EPS beat(8)-14.9%
EPS beat(12)5
Avg EPS beat(12)-2.89%
EPS beat(16)7
Avg EPS beat(16)192.59%
Revenue beat(2)0
Avg Revenue beat(2)-58.31%
Min Revenue beat(2)-59.38%
Max Revenue beat(2)-57.23%
Revenue beat(4)2
Avg Revenue beat(4)74.18%
Min Revenue beat(4)-59.38%
Max Revenue beat(4)376.59%
Revenue beat(8)3
Avg Revenue beat(8)13.93%
Revenue beat(12)6
Avg Revenue beat(12)15.34%
Revenue beat(16)7
Avg Revenue beat(16)6.41%
PT rev (1m)14.77%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.16%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.03%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 16.76
P/FCF N/A
P/OCF N/A
P/B 1.06
P/tB 1.09
EV/EBITDA N/A
EPS(TTM)-3.92
EYN/A
EPS(NY)-3.75
Fwd EYN/A
FCF(TTM)-3.44
FCFYN/A
OCF(TTM)-3.39
OCFYN/A
SpS0.57
BVpS9.01
TBVpS8.75
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -35.6%
ROE -42.99%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 98.78%
FCFM N/A
ROA(3y)4.47%
ROA(5y)-10.64%
ROE(3y)7.69%
ROE(5y)-11.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 40.11%
Cap/Sales 8.23%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.94
Quick Ratio 8.94
Altman-Z 2.07
F-Score3
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)495.59%
Cap/Depr(5y)360.98%
Cap/Sales(3y)10.41%
Cap/Sales(5y)29.92%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.87%
EPS Next Y13.59%
EPS Next 2Y8.8%
EPS Next 3Y6.96%
EPS Next 5Y9.45%
Revenue 1Y (TTM)-33.82%
Revenue growth 3Y4.1%
Revenue growth 5Y51.78%
Sales Q2Q%-9.81%
Revenue Next Year-12.53%
Revenue Next 2Y-37.81%
Revenue Next 3Y-21.54%
Revenue Next 5Y27.39%
EBIT growth 1Y18.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year54.25%
EBIT Next 3Y15.07%
EBIT Next 5Y12.04%
FCF growth 1Y-130.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-128.52%
OCF growth 3YN/A
OCF growth 5YN/A